GlassScriptPhysician profile
Dennis Mitchell Demby
NPI 1780612523
$4,821.85
in general payments reported to CMS, 2019-2025
39 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,569 · 2020: $447 · 2021: $637 · 2022: $402 · 2023: $401 · 2024: $787 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $898.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $568.82 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.67 | 2019-2024 | |
| Glaxosmithkline, LLC. | $381.73 | 2019-2025 | Trelegy Ellipta, Rotarix, Pediarix |
| Lilly USA, LLC | $360.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $189.83 | 2019-2022 | |
| Amarin Pharma, INC. | $179.96 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $169.49 | 2022-2025 | |
| Abbvie INC. | $146.44 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $142.58 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $121.70 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Grifols USA, LLC | $116.41 | 2019-2020 | |
| Daiichi Sankyo INC. | $111.65 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.01 | 2019-2023 | Glassia |
| Astrazeneca Pharmaceuticals LP | $81.74 | 2024-2025 | Airsupra, Farxiga |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Demby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.